"It is important to note that in Year 1 there were no differences in venous thrombolic events or ATEs; however, there was a significantly higher rate of serious systemic AEs (of which 80.5 % were associated with hospitalisation) with bevacizumab compared with ranibizumab, which remained significantly higher after adjustment for baseline demographics and coexisting illnesses (p00.04) [16] ." "Existing clinical evidence comes solely from clinical studies, with a number of studies reporting trends towards an increased risk of systemic AEs with bevacizumab [16] [17] [18] [59] [60] [61] ."
